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Abstract: Almost all series reporting on the results of resection in
thymic tumors indicate that the performance of a complete resection
is probably the most important prognostic factor. This issue is not a
factor in Masaoka stage I and II tumors that are almost always easily
completely resected and have an excellent prognosis. Masaoka stage
III tumors that invade the pericardium, lungs, or great vessels have
relatively higher incomplete resection rates, significantly higher
recurrence rates, and thus a worse prognosis. There are several small
reports on the efficacy of resection of the great veins when involved
by a thymic malignancy with low morbidity and meaningful long-
term survival. Superior vena cava reconstruction is commonly per-
formed by a polytetrafluroethylene, venous, or pericardial graft.
These cases can usually be identified preoperatively and, thus,
considered for induction therapy. Because these types of cases are
almost always of marginal respectability in terms of obtaining a true
en bloc resection, there is an increasing enthusiasm for offering
induction therapy in an effort to enhance resectability. Preliminary
results suggest increased R0 resection rates and improved survival
with induction therapy for locally advanced tumors. The optimal
induction treatment is unknown. The ultimate extended surgery for
advanced thymic tumors is an extrapleural pneumonectomy per-
formed for extensive pleural disease (Masaoka stage IVA). These
rarely performed operations are done for IVA disease found at initial
presentation and for recurrent disease as a salvage procedure. Again
these advanced patients are probably best managed by induction
chemotherapy followed by resection.
Key Words: Thymic malignancy, Superior vena cava resection,
Pleuropneumonectomy.
(J Thorac Oncol. 2010;5: S344–S347)
Almost all series reporting on the results of resection inthymic tumors indicate that the performance of a com-
plete resection is probably the most important prognostic
factor.1 This issue is not a factor in Masaoka stage I and II
tumors that are almost always easily completely resected and
have an excellent prognosis. Masaoka stage III tumors that
invade the pericardium, lungs, or great vessels have relatively
higher incomplete resection rates, significantly higher recur-
rence rates, and thus a worse prognosis.1–3 Resection of the
pericardium or lung usually represents little technical chal-
lenge and will not be commented on further. Resection of the
great veins represents more of a technical challenge, seems to
be associated with a relatively poor prognosis, and is increas-
ingly performed.4–6 Simple innominate vein invasion is usu-
ally managed by simple resection without reconstruction with
little short-term morbidity. Several reports suggest that in-
nominate vein invasion is a poor prognostic factor.4–6 As
such if invasion is identified before resection, strong consid-
eration should be given for induction therapy to increase the
chance of a R0 resection (Figure 1).
SUPERIOR VENA CAVA INVASION
Superior vena cava (SVC) invasion by lung or medi-
astinal tumors has been addressed either by lateral tangential
excision (for limited areas of invasion) or by SVC resection
and reconstruction (for extensive invasion or endovascular
tumor). Accumulating experience with the more common
scenario of lung cancer invasion has led to increasing use of
SVC resection in thymic tumors.7–12 There are no significant
series detailing the results of SVC resection in just thymic
tumors, so results must be extrapolated to an extent from the
large reported series, which typically entail a mixture of
malignancies. Most authors have concluded that for T4 lung
cancer with SVC invasion, the results are worthwhile with
relatively limited perioperative morbidity and mortality (in
the absence of N2 disease and with a R0 resection).9,10
Similarly, most authors have concluded that SVC resection is
worthwhile in thymic tumors as long as there is a reasonable
chance of completing a R0 resection.7–12 Given the typical
biology of thymic tumors of local invasion with rare extratho-
racic metastases and the importance of a complete resection,
SVC resection makes biologic sense, especially when com-
pared with lung cancer. Most if not all the patients should
undergo induction chemotherapy (or chemoradiotherapy) in
an effort to downstage the tumor as much as possible. The
usual sequence is induction chemotherapy, then resection,
and then adjuvant radiation. Several series of unresectable or
advanced Masaoka stage III tumors have been reported,
suggesting a benefit to induction therapy with increased R0
resection rates and improved survival.13,14 The contrast en-
hanced computed tomography scan should be scrutinized
carefully by the thoracic surgeon to look for extensive abut-
ment, invasion, or intraluminal tumor within the innominate
vein and SVC (Figure 2). Usually an accurate prediction can
be made preoperatively of the likely need for SVC resection.
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TECHNIQUE OF SVC RESECTION
The anesthesiologist should be alerted to the possibility
of SVC resection. Intravenous access should be secured in
both the arm and below the diaphragm. When the SVC is
clamped, the head of the bed should be raised to enhance
venous drainage of the brain. The blood pressure should be
controlled and increased if needed after clamping to maintain
cerebral perfusion pressure.15 Patients who have the SVC
syndrome with complete occlusion preoperatively obviously
tolerate SVC clamping without any issues. Typically, the
resection of the tumor is carried out until the tumor is left
only attached to the SVC before SVC clamping, resection,
and reconstruction. This minimizes clamp time and facilitates
expeditious reconstruction with the specimen out of the way.
Usually the phrenic nerve is involved if the SVC is invaded,
and so, it must be resected as well. Consideration should be
given to a concomitant diaphragm plication to minimize
postoperative dyspnea. Lateral resection can be done for
limited (25%) circumference involvement. Repair can be
performed with autologous vein, autologous or bovine peri-
cardium, arterial homografts, or polytetrafluroethylene
(PTFE) vascular patch.
For the more common extensive involvement, complete
SVC resection and reconstruction are performed. Usually the
right innominate vein is anastomosed to the neo-SVC. Alter-
native reconstructions include those of SVC to SVC, left
innominate to SVC, and right internal jugular to SVC. If a
choice needs to be made between using either the right or the
left innominate vein, most surgeons chose the right as it is
usually larger, lies in a more direct plane, and graft length
estimation is easier because the retractor does not need to be
closed for right length estimation. Most surgeons have aban-
doned Y type of reconstructions of both innominate veins
because of poor long-term patency rates, presumably due to
reduced flow compared with unilateral grafts.8 Repair can be
performed with a spiral vein graft, a bovine pericardium tube
graft (typically made by stapling a sheet into a tube over a
cylindrical mandrill), an arterial homograft, or a ringed PTFE
graft.7–17 Most surgeons use ringed PTFE grafts because of
their easy availability and good long-term results. If needed,
resections may extend to encompass the right atrium.17
Anticoagulation after SVC resection and reconstruction is
variable and controversial with no clear consensus. Most
surgeons either recommend permanent aspirin or at least
short-term warfarin anticoagulation to reduce the risk of
SVC thrombosis.10
RESULTS OF SVC RESECTION
Perioperative morbidity and mortality are quite low
from SVC resection (Table 1). Specific complications related
to SVC resection include hemodynamic instability because of
intraoperative clamping, early SVC graft thrombosis, and
cerebral edema from prolonged SVC clamping. There is also
a risk for late SVC graft thrombosis from 5 to 10%. Survival
was not reported in any series for thymic tumors alone. Two
series reported on mediastinal tumor survival with 5-year
estimates of approximately 50% (Table 1).9,10
FIGURE 1. A computed tomography scan of a patient with
left innominate vein invasion with intraluminal tumor from a
thymic carcinoma.
FIGURE 2. A computed tomography scan of a patient with
superior vena cava (SVC) compression and infiltration from a
B3 thymic tumor. Note the deformity of the anterior wall of
the SVC. Resection and reconstruction were necessary.
TABLE 1. Results of SVC Resection in Thymic Tumors
References
No. of Cases
(Thymic/Total)
Operative
Mortality
(%)
Graft
Patency Survival
Shintani et al.7 11/18 0 7/10 NS
Chen et al.8 11/15 0 15/15 14/15 alive
with 35 mo
follow-up
Spaggiari et al.9 9/70 4 (7.7) 64/70 45%, 5 yr
Lanuti et al.10 3/19 1 (5) 17/19 56%, 5 yr
Leo et al.11 8/72 2 (2.8) 70/72 NS
Okereke et al.,
in press
10/38 2 (5) 36/38 27/38 alive
SVC, Superior vena cava; NS, not stated.
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PLEUROPNEUMONECTOMY FOR EXTENSIVE
IVA DISEASE
Thymic tumors have a predilection for pleural metas-
tases both at initial presentation of locally advanced tumors
and with recurrent tumors. Minimal pleural disease is typi-
cally treated by regional or complete parietal pleurectomy in
conjunction with chemotherapy (Figures 3, 4).18 Extensive,
often confluent pleural disease is usually also associated with
widespread lung invasion and requires pleuropneumonec-
tomy for near complete resection. Although at first glance this
seems like heroic surgery, the biology of this tumor with long
survival even with a recurrence favors an aggressive ap-
proach. Numerous case reports have demonstrated the feasi-
bility of this concept. More recently, several small series have
been reported that demonstrate reasonable results (Table
2).19–21 Although a true en bloc complete resection cannot be
performed, the amount of disease that is left is typically not
visible and truly microscopic. Most cases require resection of
the ipsilateral pericardium and diaphragm as well, similar to
that of mesothelioma resection. Typically induction chemo-
therapy is given before resection to maximize any possible
downstaging. Radiation should be given rarely as an induc-
tion agent, because the lung and pleura will be removed and
the involved field is quite large, leading to increased toxicity.
Radiation is typically given as an adjuvant for any areas the
surgeon had a concern for intraoperatively. Similar to me-
sothelioma treatment, it is easier and safer to give radiation to
the hemithorax once the lung is removed.
TECHNIQUE OF PLEUROPNEUMONECTOMY
FOR EXTENSIVE IVA DISEASE
The preoperative cardiopulmonary evaluation should
be through in these patients because a pneumonectomy is a
significant physiologic insult. Complete pulmonary func-
tion tests, a quantitative ventilation perfusion scan if lung
function is abnormal, an echocardiogram, and a stress test
if there is any suspicion of coronary disease are the
standard tests. A positron emission tomography or com-
puted tomography scan is helpful to eliminate the possibility
of extrathoracic disease before this major resection. Most
surgeons use a posterolateral thoracotomy for the operative
approach. Others have described a mediansternotomy ap-
proach or a clamshell/hemiclamshell approach. In large part,
this revolves around the extent of the mediastinal component
of the tumor, with larger tumors benefitting from anterior
access rather than lateral access.
The typical patient is resected by a large posterolateral
thoracotomy with division of both the latissimus and the
serratus anterior muscles.22 Usually the sixth rib is resected to
enhance access. Often a lower thoracotomy is done under the
FIGURE 3. A computed tomography scan of an isolated
parietal pleural metastases from a recurrent B2 thymoma
after resection in the left paravertebral gutter. A local pleu-
rectomy was performed after chemotherapy.
FIGURE 4. A computed tomography scan of a large B3
thymoma with extensive lung and pleural involvement,
which required pleuropneumonectomy for resection.
TABLE 2. Results of Pleuropneumonectomy for Thymic
Tumors
References
No. of
Patients
(Thymoma/
Cancer)
Induction
Therapy Mortality
Adjuvant
Therapy Survival
Wright19 5, all B3 2/5 0 5/5 75%, 5 yr
Huang
et al.20
4, all thymomas 4/4 0 4/4 78%, 5 yr
Ishikawa
et al.21
4, all thymomas 4/4 0 3/4 75%, 5 yr
Wright Journal of Thoracic Oncology • Volume 5, Number 10, Supplement 4, October 2010
Copyright © 2010 by the International Association for the Study of Lung CancerS346
divided latissimus to enhance access to the diaphragm if
needed. The subpleural plane is entered bluntly with the
surgeon’s fingers, and a complete resection of the parietal
pleura is done off the anterior, lateral, and posterior chest
walls. The mediastinal pleura is dissected next with care to
avoid injury to important mediastinal structures such as the
vagus, aorta and arch vessels, esophagus, and azygos. The
pericardium is entered at its periphery and resected as well.
The artery and two veins to the lung are stapled and divided
followed by the bronchus. The diaphragm is usually resected.
If so and if there is minimal diaphragm involvement, it is
useful to maintain the peritoneum relatively intact. The dia-
phragm is reconstructed with PTFE with anchoring to the
chest wall with nonabsorbable sutures. The pericardium is
reconstructed with PTFE with fenestrations or with absorb-
able mesh.
RESULTS OF PLEUROPNEUMONECTOMY FOR
EXTENSIVE IVA DISEASE
The results of pleuropneumonectomy are rather good
despite the aggressive nature of the operation.19–21 The peri-
operative morbidity and mortality that have been reported are
rather low and probably reflect in part careful patient selec-
tion and also an absence of smoking on the patient population
(Table 2). The reported 5-year survival in the three larger
series is approximately 75% and is quite remarkable (Table
2).19–21 Caution is in order although as many recurrences
occur after 5 years, and there is usually a long time between
recurrence and death. Nonetheless, these results seem to
justify this aggressive approach to this rare subset of thymic
tumor patients.
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